Breaking News

Secarna, Evotec Form Strategic Antisense Alliance

To develop novel antisense oligonucleotide therapeutics across a broad range of targets and indications.

By: Contract Pharma

Contract Pharma Staff

Evotec SE and European antisense drug discovery company, Secarna Pharmaceuticals GmbH & Co. KG entered a strategic partnership in the field of antisense oligonucleotide (“ASO”)-based therapeutics. Antisense therapy is a highly-targeted pharmacological approach which interferes with gene expression in the cells of interest to specifically inhibit the production of proteins which promote development and progression of diseases. Secarna combines its LNAplus platform with cutting...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters